E75.23 Krabbe disease

Name of the Condition

• Krabbe disease (ICD-10 Code: E75.23)

Summary

Krabbe disease is a rare inherited lysosomal storage disorder characterized by the abnormal accumulation of galactocerebroside, a type of sphingolipid, in cells. This buildup disrupts normal cellular function, particularly affecting the nervous system, and is part of a broader group of sphingolipid metabolism disorders. The condition presents with progressive neurological decline, often manifesting in infancy or early childhood, though severity and onset can vary.

Causes

Krabbe disease results from mutations in the GALC gene, which encodes the enzyme galactocerebrosidase. These mutations impair the enzyme's ability to break down galactocerebroside, leading to its buildup in tissues. Inheritance is typically autosomal recessive, meaning both copies of the gene must be mutated for the condition to manifest.

Risk Factors

• Family history of Krabbe disease or related lysosomal storage disorders.
• Consanguineous relationships, increasing the likelihood of recessive gene mutations.
• Ethnic backgrounds with higher carrier frequencies for GALC mutations.

Symptoms

• Progressive neurological deterioration, including developmental delay or regression.
• Muscle weakness, hypotonia, or spasticity.
• Seizures or abnormal eye movements.
• Loss of motor skills or speech.
• Irritability or feeding difficulties (in infants).

Diagnosis

Diagnosis involves clinical evaluation of symptoms, followed by laboratory testing to measure galactocerebrosidase enzyme activity. Genetic testing may confirm mutations in the GALC gene. Imaging studies, such as MRI, may show characteristic changes in the brain, and nerve conduction studies can assess peripheral nerve function.

Treatment Options

Treatment is primarily supportive and may include physical therapy, occupational therapy, and medications to manage symptoms like seizures. Hematopoietic stem cell transplantation (HSCT) may be considered in early-stage cases to slow disease progression, though outcomes vary. No cure exists for the condition.

Prognosis and Follow-Up

Prognosis is generally poor, especially for infants with early-onset disease, who often succumb to the condition within the first few years of life. For those with later-onset forms, progression may be slower, but neurological decline is typically irreversible. Regular follow-up with neurologists and other specialists is essential to monitor symptoms and adjust care plans.

Complications

• Severe neurological impairment, including loss of motor and cognitive function.
• Respiratory failure due to muscle weakness.
• Feeding difficulties leading to malnutrition.
• Increased risk of infections due to compromised immune function.

Lifestyle & Prevention

There is no known way to prevent Krabbe disease. Genetic counseling is recommended for families with a history of the condition to discuss carrier testing and reproductive options. Prenatal testing may be available for at-risk pregnancies.

When to Seek Professional Help

Seek immediate medical attention if symptoms of progressive neurological decline appear, especially in infants or young children, such as developmental regression, muscle weakness, or seizures. Early diagnosis is critical for potential intervention.

Tips for Medical Coders

When coding for Krabbe disease, use ICD-10-CM code E75.23. Ensure documentation supports the diagnosis, including clinical findings, enzyme activity results, or genetic testing. Note that this code is specific to Krabbe disease and should not be used for other sphingolipidoses. Verify that the code aligns with the patient's clinical presentation and any associated complications.